Insud Pharna has recently completed its acquisition of Agile through the merger of an indirect, wholly owned subsidiary of Insud. 

The former holders of Agile common stock voted to approve the acquisition at a special meeting of stockholders on August 22, 2024. Upon closing of the acquisition, former shareholders of Agile became entitled to receive USD 1.52 per share in cash, net of assumed liabilities and estimated transaction costs, for an approximate total enterprise value of USD 45 million.

Insud completed its acquisition of Agile through the merger of an indirect, wholly owned subsidiary of Insud with Agile continuing as the surviving company and becoming an indirect subsidiary of Insud under a definitive merger agreement dated as of June 25, 2024. With the completion of the transaction, Agile will no longer be listed on any public market.

Insud Pharma is a pharmaceutical group with more than 45 years of history, with a presence in around 50 countries, 9,000 employees worldwide, and 20 manufacturing plants.

Insud Pharma operates throughout the value chain of the pharmaceutical industry, offering specialized knowledge in scientific research, development, manufacturing, sale and marketing of a wide range of active pharmaceutical ingredients (APIs), finished dosage forms (FDFs) and pharmaceutical products of the brand for the care of humans and animals and biopharmaceuticals.